	US 12,336,976 B2
	Glutaminase inhibitor therapy
Timothy Heffernan, Sugar Land, TX (US); Jeffrey Kovacs, Pearland, TX (US); Nakia Spencer, Houston, TX (US); and Christopher Bristow, Houston, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Sep. 6, 2023, as Appl. No. 18/461,724.
Application 18/461,724 is a continuation of application No. 17/327,225, filed on May 21, 2021, granted, now 11,786,500.
Application 17/327,225 is a continuation of application No. 16/891,791, filed on Jun. 3, 2020, granted, now 11,045,443, issued on Jun. 29, 2021.
Application 16/891,791 is a continuation of application No. 16/164,581, filed on Oct. 18, 2018, granted, now 10,722,487, issued on Jul. 28, 2020.
Claims priority of provisional application 62/573,906, filed on Oct. 18, 2017.
Prior Publication US 2024/0165070 A1, May 23, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/50 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/4196 (2006.01); A61K 31/433 (2006.01); A61K 31/501 (2006.01); A61K 31/55 (2006.01); A61K 33/243 (2019.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01); A61K 51/04 (2006.01)

CPC A61K 31/282 (2013.01) [A61K 31/337 (2013.01); A61K 31/4196 (2013.01); A61K 31/433 (2013.01); A61K 31/501 (2013.01); A61K 31/55 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); G01N 33/57449 (2013.01); A61K 51/0408 (2013.01)]

14 Claims

1. A method of identifying a subject's responsiveness to GLS-1 inhibitor therapy and treating cancer in said subject, comprising determination of a low level of expression or concentration of ASNS in said subject and administering one or more glutathione lowering agents to said subject.